CT 0180
Alternative Names: CT-0180; CT0180 - CARsgenLatest Information Update: 28 Apr 2024
At a glance
- Originator CARsgen
- Developer CARsgen; Zhejiang University
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 02 Jun 2023 Adverse events and efficacy data from a Liver cancer (Late-stage disease, Second-line therapy or greater) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2022 Pharmacodynamics data from preclinical studies in Liver cancer released by CARSgen